Scientific Presentations Detail Progress with VeraTag(TM) Assays in Breast
Cancer
SOUTH SAN FRANCISCO, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc. (Nasdaq: MGRM) today announced five posters to be
presented at the 30th San Antonio Breast Cancer Symposium taking place in
San Antonio, TX, from December 13 - 16, 2007. Following are details for
each embargoed session:
-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST
Abstract # 2007: Quantitative measurements of HER2 expression and
HER2:HER2 dimerization identify subgroups of HER2 positive metastatic
breast cancer patients with different probabilities of response to
trastuzumab treatment. (Presenter: W. Huang)
-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST
Abstract # 2011: Development of novel proximity-based immunoassays for
the detection of HER heterodimerization in breast cancer cell line
lysates and formalin-fixed, paraffin-embedded tissue.
(Presenter: L. Eli)
-- Friday, December 14th, 2007, 7.00 am - 9.00 am CST
Abstract # 2012: Characterization of a novel proximity immunoassay for
the quantitative determination of HER2 protein expression and HER2
homodimerization in formalin-fixed, paraffin-embedded breast cancer
tissue. (Presenter: J. Winslow)
-- Saturday, December 15th, 2007, 7.00 am - 9.00 am CST
Abstract # 4108: Profiling HER-family receptor dimerization in HER2
over expressing cells that co-express mutated EGFR receptors.
(Presenter: R. Dua)
-- Saturday, December 15th, 2007, 5.00 pm - 7.00 pm CST
Abstract # 5002: Increased detection of breast cancer markers human
epidermal growth factor receptor dimer and downstream signaling
proteins utilizing the VeraTag technology with dextran modified
antibodies. (Presenter: J. Wallweber)
About HERmark(TM)
HERmark is a propriety diagnostic that accurately quantifies HER2
expression and dimerization in patients with breast cancer. Preliminary
data from three cohorts of trastuzumab-treated patients with metastatic
breast cancer who were identified as "HER2 positive" by conventional assays
suggest that HERMark can identify patients who are likely to respond to
Herceptin with greater precision than currently available tests, permitting
stratification of patients according to their degree of clinical benefit
from the drug. Additional studies of HERmark for breast cancer in both the
metastatic and adjuvant settings are in progress.
About VeraTag(TM)
VeraTag is a proximity-based assay technology platform that accurately
quantifies proteins and functional protein complexes. This platform
provides a researcher or clinician a more thorough understanding of
protein-protein interactions or signaling pathway activity allowing for
disease characterization at the molecular level. VeraTag is designed to run
on standard formalin-fixed paraffin embedded (FFPE) patient samples.
About Monogram
Monogram is advancing individualized medicine by discovering,
developing and marketing innovative products to guide and improve treatment
of serious infectious diseases and cancer. The Company's products are
designed to help doctors optimize treatment regimens for their patients
that lead to better outcomes and reduced costs. The Company's technology is
also being used by numerous biopharmaceutical companies to develop new and
improved anti-viral therapeutics and vaccines as well as targeted cancer
therapeutics. More information about the Company and its technology can be
found on its web site at http://www.monogrambio.com.
VeraTag and HERmark are trademarks of Monogram Biosciences, Inc.
Contacts: Alfred G. Merriweather Jeremiah Hall
Chief Financial Officer Feinstein Kean Healthcare
Tel: 650 624 4576 Tel: 415 677 2700
amerriweather@monogrambio.com jeremiah.hall@fkhealth.com
SOURCE Monogram Biosciences, Inc.
 back to top
Related links:
http://www.monogrambio.com
http://www.sabcs.org
http://www.prnewswire.com/comp/638944.html /
CONTACT:
Alfred G. Merriweather, Chief Financial
Officer of Monogram Biosciences, Inc., +1-650-624-4576,
amerriweather@monogrambio.com, or Jeremiah Hall of Feinstein Kean
Healthcare, +1-415-677-2700, jeremiah.hall@fkhealth.com, for
Monogram Biosciences, Inc.
|
